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Objective: The idea behind switch therapy is that antibiotic treatment should be changed from the parenteral to 
another suitable route (usually oral) as soon as the patient‘s condition allows. This option is cost-effective in terms of 
both acquisition costs (oral antibiotics are less expensive than their parenteral counterparts) and indirect costs, and 
patients may be discharged home sooner. This not only releases hospital beds but is also popular with patients and has 
other advantages. There are relatively few formal clinical trials, most often using oral third-generation cephalosporins 
and fluoroquinolones; these agents at present seem the most appropriate to  use after parenteral antibiotics have been 
stopped (usually after 2 to  3 days). Logistic aspects are important, and close collaboration is required between 
pharmacists, physicians and microbiologists. Further trials are needed in specific patient groups and with other antibiotic 
regimens to validate the efficacy of switch therapy. 
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In most instances where patients acquire infections in 
hospital, or are admitted to hospital having developed 
an infection at  home, antibiotic therapy must be started 
before there has been time to determine the precise 
bacterial etiology. The choice of antibiotic is, therefore, 
made empirically, by a process known generally as ‘best 
guess’. The microbiological factors needing to be 
considered include the following: the wide range of 
possible pathogens, rising incidences of resistance (due 
either to the intrinsic resistance of species such as 
Pseudomonas aeruginosa, or acquired resistance due to 
transfer of plasmids) and the necessity of providing 
effective therapy first time if the patient is immuno- 
compromised. Other important matters relevant to the 
decision concerning initial therapy are: existing 
antibiotic policies, the site of infection, toxicity, drug 
interactions and allergy. 
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As a result of these considerations, many clinicians 
choose as routine first-line therapy either an amino- 
glycoside (sometimes, depending upon circumstances, 
in combination with an antipseudomonal 0-lactam) or 
a third-generation cephalosporin. A fluoroquinolone 
(ciprofloxach or ofloxacin) will often be reserved, for 
reasons of cost, for special situations. It is usually 
necessary to administer the antibiotic intravenously in 
seriously ill and shocked patients. Oral therapy, except 
in the case of urinary infections, is inappropriate, even 
if the patient is able to swallow and keep down the 
medication, as tissue levels may prove inadequate in 
seriously ill patients, due to impaired absorption [I]. 
COSTS OF PARENTERAL ANTIBIOTICS AND 
HOSPITAL STAY 
The ‘acquisition cost’ of parenteral antibiotics is almost 
always greater than that of their corresponding oral 
counterparts (where strict equivalents are available - see 
below). For example, in the UK ciprofloxacin and 
amoxycillin are, weight for weight, 33 times and twice, 
respectively, as expensive as injectable than as oral 
formulations [2]. Furthermore, injectable antibiotics 
are more costly to administer, monitoring may be 
required, and their use means that patients must usually 
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stay in hospital during the coui-se of treatment, which 
is often scheduled for 7 to 10 days. The latter can be 
extremely expensive: for example, a bed in a specialist 
unit a t  a university hospital in London may cost in 
excess of A350 per day. In the USA, the average daily 
cost of occupying a hospital bed has recently been 
estimated as $752 [3]. These ‘hidden costs’ of parenteral 
therapy must be added to the acquisition costs. 
Estimating the true cost of therapy in hospitals is 
a highly complex science [4], but pharmacoecononiic 
analysis must now be attempted, in view of demands 
for containinent of healthcare costs imposed by govern- 
ments and other financial providers (e.g. insurance 
companies). 
DECREASING THE COST OF A COURSE OF 
ANTIBIOTIC TREATMENT 
It is clear that there are several interventions that can be 
made in order to decrease overall costs. 
Acquisition costs may be diminished by decreasing 
the dose of antibiotic and/or increasing the interval 
between doses, or by substituting a cheaper antibiotic 
for the initial empirical choice once the infecting 
organism and its sensitivities are known. The question 
must also be asked as to whether initial therapy has to 
be by the parenteral route [5,6]. For example, in 
pneumonia oral antibiotics may suffice in the absence 
of vomiting but in severely ill patients parenteral 
therapy is essential [7]. 
Better cost-effectiveness will also result from inter- 
ventions that allow the patient to leave hospital earlier. 
One possible means to this end, adopted in the USA, 
Israel and The Netherlands [8], is for patients to 
continue intravenous treatment with antibiotics at 
home. Such an approach has not yet found wide 
application in other countries, and is not without 
hazards [9]. While it is cost-effective in terms of freeing 
hospital beds, expensive intravenous antibiotics are still 
required, and extra costs are imposed by specialist home 
infusion teams being required under certain circuni- 
stances. 
An alternative strategy, of changing as soon as 
possible from intravenous to oral antibiotics, seems 
more attractive, especially when it allows patients to 
vacate a hospital bed and continue treatment at  home. 
Both acquisition and hidden costs are cut in this way. 
This procedure, variously called ‘step-down’, ‘switch’, 
‘sequential’ and ‘follow-on’ therapy, can now be more 
generally applied due to the introduction of new oral 
compounds (see below). It will be referred to here as 
‘switch’. The convenient formal definition as ‘an early 
transition from parenteral to oral therapy’ [lo] is too 
restrictive. as it does not take into account non- 
parenteral routes other than oral (such as rectal 
adniinistrdtion of metronidazole or ciprofloxacin given 
via a nasogastric tube). A revised working definition is 
thus ‘an early transition from parenteral to non- 
parenteral therapy’. 
THE CONCEPT OF ’SWITCH’ THERAPY 
Like many good ideas, switch therapy looks, with the 
benefit of hindsight, an obvious concept. However, it 
has taken a relatively long time to become formalized 
in the antibiotic field. Early examples were in pediatric 
practice, for the treatment of osteomyelitis and septic 
arthritis. Tetzlaff et al. [l I] and Prober and Yaeger 1121 
successfully switched from intravenous to oral fi- 
lactains, using a variety of different compounds (e.g. 
parenteral methicillin, cefazolin, nafcillin or ampicillin 
followed by oral cephalexin, penicillin V, ampicillin, 
dicloxacillin or cloxacillin), while Feigin et al. [13] 
switched from intravenous to oral clindamycin. Shann 
et al. [14,15] successfully switched from intraniuscular 
to oral chloramphenicol in meningitis and pneumonia 
in children hospitalized in Papua New Guinea. These 
studies were very valuable pointers to the way ahead, 
but their value is diminished by not being formal, 
randomized clinical trials. 
It is important at this stage to understand that not 
all antibiotics given by the oral route are completely 
absorbed, even in healthy volunteers (Table 1). As 
absorption following oral administration may be less 
than optimal in ill patients in hospital, it is clearly 
necessary, if possible, to select a well-absorbed 
antibiotic and to give it in a larger dose than that used 
in the initial parenteral regimen. 
In 1987 Quintiliani et al. [16] laid the foundations 
for a scientific approach to switch therapy, in a 
thoughtful discussion of the merits of ‘streamlining 
Table 1 Oral bioavailability of some oral antibiotics 
Bioavailability 
Cefaclor Amoxycillin Anipicillin 
Cefadroxil Ampicillin esters Cefixime 
Cephalrxin Ceftibuten Cefpodoxime 
Cephradine Erythromycin’ Cefuroxime axeti1 
Chloraniphenicol Flucloxacillin Cloxacillin 
Ciprofloxacin Oxytetracycline Norfloxacin 
Clindamycin Penicillin V’ 
Doxycycline 
Minocycline 
Ofloxacin 
Trimethoprim 
’Variable 
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antibiotic administration’. However, only a small part 
of this paper concerned switching to oral treatment. 
This was followed two years later by a large clinical trial 
of ‘switch’ [17], where patients with upper urinary 
tract infections were randomized to either intravenous 
ceftriaxone for the whole treatment period (in this case, 
15 days) or intravenous ceftriaxone for 4 days followed 
by oral cefixime for 11 days. Many would criticize the 
design of this study, on the basis that a 15-day course 
of treatment is excessive for the indication. However, it 
can be regarded as a landmark in the process of 
formalizing the concept of switch. Surprisingly in view 
of the hopeful findings in that trial, since then there 
have been relatively few definitive publications. Despite 
the comparative absence of hard data, however, ‘switch’ 
has become firmly established in some circles, being 
discussed not only in the clinical literature but also, 
significantly, in journals read by hospital administrators. 
Switch is now accepted as common practice by the 
FDA, and has been written into their General Con- 
siderations for Clinical Trials [18]. 
While many clinicians will already informally have 
adopted a policy of switching to oral therapy when 
there has been a good initial response to parenteral 
antibiotics, it is clearly more satisfactory if this action is 
made part of an official policy. O n  the other hand, 
some infectious disease physicians consider that 
intravenous treatment should continue for the whole 
course [19], while others considering adopting switch 
may be deterred by either the lack of convincing data 
from clinical trials, the absence of specific guidelines as 
to when switch might best be instituted [ 3 ] ,  or by 
uncertainty as to which oral antibiotic to use as the 
switch agent. 
WHEN IS SWITCH APPROPRIATE? 
Switch within a few days of the initiation of antibiotic 
therapy can be considered in the following circum- 
stances [10,20]: 
1. There are no longer clinical indications for intra- 
venous therapy. 
2. Oral foods and fluids are tolerated, and there is no 
reason to believe that gastrointestinal absorption is 
abnormal. If the patient is taking oral medication 
such as antacids or sucralfate, it must be remembered 
that these might interfere with the absorption of 
ciprofloxacin, and thus tip the scales against using 
this agent for switch. 
3.  The temperature has returned to normal, signs and 
symptoms relevant to the infective process are 
improving and any abnormality in blood count is 
subsiding. 
If there is any doubt about the fulfillment of the 
above criteria, it is suggested that parenteral treatment 
should continue, with daily review. 
Quintiliani et al. [21] found that about 75% of all 
patients hospitalized with an infection were eligible for 
early switch. 
Conditions for which switch seems most appro- 
priate include nosocomial pneumonias, presumed 
sepsis of unknown etiology, infections involving the 
urogenital tract, Gram-negative septicemia, infections 
of skin and soft tissues and intra-abdominal infections 
[10,22]. 
CHOICE OF ANTIBIOTIC FOR SWITCH 
The oral antibiotic chosen to replace the original 
parenteral treatment has to be selected carefully. It must 
have an appropriate antibacterial spectrum, have 
satisfactory pharmacokinetics and pharmacodynamics, 
and be ofproven clinical efficacy in the condition being 
treated [22]. Oral third-generation cephalosporins, 
fluoroquinolones and co-amoxiclav fulfill these criteria 
in most respects, but the choice may be restricted in the 
case of certain infecting organisms, such as staphylo- 
cocci, Pseudomonas aevuginosa or Enterobacter spp. 
The simplest procedure would be to give the same 
antibiotic by mouth as was being used parenterally, 
possibly in a larger dose. This approach is only practic- 
able in the case of certain pharmaceutically versatile 
antibiotics such as trimethoprim, co-amoxiclav, amoxy- 
cillin, ciprofloxacin, ofloxacin, erythromycin and clinda- 
mycin. In patients where initial intravenous treatment 
has been with one of these compounds, switch is 
straightforward. For example, a patient with acute 
pyelonephritis who is substantially improved following 
treatment for 2 days with an initial ‘best guess’ regimen 
of intravenous ampicillin + gentamicin may be switched 
to oral ampicillin, provided that the infecting organism 
has been shown to be sensitive. However, as suggested 
above, most ‘best guess’ treatment of serious infections 
will start with a cephalosporin given intravenously. If a 
switch approach is required here, the practitioner 
wishing to stay with the same therapeutic class has only 
a limited choice of follow-on oral antibiotics. Very few 
of the first- and second-generation cephalosporins (i.e. 
only cephradine and cefuroxime) can be used both by 
injection and orally. Neither cephradine nor cefur- 
oxime is used commonly as primary therapy of serious 
nosocomial infections, as both lack activity against 
hospital pathogens such as Serratia rnarcescens, many 
indole-positive Proteae and Enterobacter spp. Thus, 
although they are available for switch therapy, 
cephradine and cefuroxime (as its prodrug, cefuroxime 
axetil) have rarely been used for this purpose, as usually 
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they will not be appropriate. In particular, sonie older 
practitioners may have experienced problems with 
highly variable bioavailability of cefuroxime axetil [23], 
that, although now rectified by reformulation, may 
have a perinanent deterrent effect. 
The most obvious choices for the oral component 
of switch therapy are the oral third-generation cephalo- 
sporins (such as cefixime, cefpodoxime, ceftibuten and 
cefetamet), fluoroquinolones (ciprofloxacin, ofloxacin) 
and co-amoxiclav. Any of these compounds offers, in 
terms of microbiological spectrum, pharmacokinetics 
and pharniacodynamics, a satisfactory oral follow-up to 
injectable third- and fourth-generation cephalosporiiis 
or an aminoglycoside, and thus deserves consideration 
for use in switch therapy. Each group has disadvantages 
- less than optimal bioavailability for the third- 
generation cephalosporins (Table l), relative contra- 
indication in children and doubts about clinical efficacy 
against the Pneumococcus for the fluoroquinolones, and 
allergy and (in the opinion of some) adverse event 
profile for co-amoxiclav. It seems both logical and 
economical that at any one institution a single agent be 
designated for use for switch therapy, and the choice 
must depend upon local factors. 
PRACTICAL APPLICATIONS OF SWITCH THERAPY 
While the concept of switch has been well developed, 
formal proofs of its efficacy are still small in number. As 
Janknegt and van der Meer [22] point out, it is 
necessary to carry out coniparative clinical trials of 
rigorous design to validate the concept in distinct 
patient groups. Thus, different antibiotic combinations 
(intravenous followed by oral) need to be tested in 
patients suffering from various types of infection. It 
may not be valid to extrapolate in general from results 
obtained under one specific set of circunistances 
(variables being drug combinations and clinical 
conditions). 
Examples of some of the clinical trials carried out 
are given in Tables 2, 3 and 4. The most valuable trials 
are those comparing switch with conventional therapy, 
i.e. a full course of intravenous treatment, summarized 
in Table 2. The trials shown in Tables 3 and 4 should 
ideally have had an extra arm, consisting of the con- 
ventional intravenous treatment. Despite these design 
differences, it is clear from the data in Tables 2, 3 and 
4 that switch therapy is effective. The majority of the 
trials listed were in adults, and the most common 
condtion studied was infection of the lower respiratory 
tract. Cefixime and ciprofloxacin were the most widely 
used antibiotics for the oral, switch, arm. 
Further examples of the ad hoc use of ciprofloxacin 
may be found in symposium proceedmgs [24]. 
The design and reporting of several of these trials 
are open to criticism: 
Several have been reported as abstracts only, or 
published in supplements, that may have been 
subject to less rigorous peer review. 
Fourteen or 15 days of treatment for an upper or 
‘complicated’ urinary tract infection [17,25] is 
longer than that usually thought necessary. 
The identity of the antibiotic used for intravenous 
therapy is not specified in two studies [26,27], one 
of which [26] is reported in abstract form only. 
The trial carried out by Paladin0 et al. [27] involved 
an unspecified ‘mix’ of different types of infection. 
Bearing in mind the limitations of these studies, 
there is no obvious clinical advantage of one regimen 
over another, but, clearly, further studies need to be 
Table 2 Comparative clinical trials of switch therapy, with conventional therapy as comparator 
Treatment 
Type of patient and infection IV Oral No. pnents  Outcome2 Reference 
Adults, 
upper urinary tract 
Children, 
febrile neutropenia 
Adults, 
lower respiratory tract 
Adults, 
respiratory tract 
Adults, 
various 
Ceftriaxone 15 days 
Ceftriaxone 4 days 
Unspecified 7-10 dayc 
Unspecified 2 days 
Cefotaxime 7-10 days 
Cefotaxime 2-3 days 
Ceftazidime 7 daysb 
Ciprofloxacin 6 daysh 
Unspecified 5 8 days 
Unspecified 3 days 
- 
Cefixime I1 davs 
- 
Cefixinie 5-8 days 
- 
Cefixime 5-8 days 
- 
Ciprofloxacin 5 days’ 
- 
Ciprofloxacin 2 5 days 
48 
47 
70 
68 
47 
47 
56 
66 
60 
62 
98% 
94% 
74%1 
71% 
94% 
94% 
90% 
91% 
83% 
79% 
17 
17 
26 
26 
49 
49 
44 
44 
27 
27 
‘Percentage of patients cured or improved. ‘Mean values. 
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Table 3 Comparative clinical trials of two different modalities of switch therapv 
~~ 
Treatment 
~~ 
Type of patient and infection IV Oral No. patients Outcomea Reference 
Children 
pneumonia 
~ 
Ceftriaxone 2 days Cefixime 6 days 29 100% 50 
Ceftriaxone 2 days Co-anioxlclav 6 days 33 94% 50 
Adults, Cefuroxinie 2-3 days Cefuroxime axetil 5 days 256 87% 51 
lower respiratory tract Co-amoxiclav 2-3 days Co-amoxlclav 5 days 256 86% 51 
’Percentage o f  patients cured or improved 
carried out using refined protocols. This is particularly 
the case for new oral third-generation cephalosporins 
(e.g. cefpodoxime) so far untried as switch agents. 
Beta-lactam agents will probably remain first choice 
as switch agents; although the fluoroquinolones have 
many suitable properties, there are some factors that 
may militate against their wide use. First, most 
clinicians might instinctively feel more at ease with a 
‘pure’ switch, i.e. cephalosporin to cephalosporin, or 
fluoroquinolone to fluoroquinolone; as cephalosporins 
are more often the initial empirical choice, this implies 
a greater popularity for a cephalosporin switch. 
Second, there may still be some reluctance, despite 
reassurances offerred [e.g. 281, to use fluoroquinolones 
in chest infections, particularly when the Pneurno- 
coccus has been involved. Third, the fluoroquinolones 
are still contraindicated in children, according to 
manufacturers’ Data Sheets. Fourth, many microbi- 
ologists work hard to discourage too wide a use of the 
fluoroquinolones for fear of resistance emerging, and 
such opinion may have some deterrent effect. This 
situation may alter when the next generation of fluoro- 
quinolones becomes generally available. 
Table 4 Non-comparative clinical trials of switch therapy 
WHEN TO SWITCH 
There can be no hard-and-fast rule concerning the 
precise timing of switching from intravenous to oral 
antibiotics. The overriding factor in all cases is the 
clinical condition of the patient under treatment. 
Quintiliani et al. [16] point out that patients with 
hospital-acquired infections go through three Astinct 
phases. 
0 During the first few days their condition is clinically 
unstable, the cause (and sometimes the source) of 
infection is usually still unknown, and empirical, 
often combination, antibiotic treatment is needed. 
0 The patient passes into phase two after about 2 or 3 
days; here, the clinical state becomes more stable, the 
identity and sensitivity of the infecting pathogen is 
known, and it is time to simplify therapy. 
0 Finally, in phase three (7 days and after) the patient 
is well on the way to recovery, and may be discharged 
on oral treatment. 
Quintiliani et al. [16], in their original discussion, 
mean by ‘simplifying therapy’ in phase two a change 
Treatment 
Type of patient and infection IV Oral No. patients Outcome’ Reference 
Adults, pneumonia Cefiizoxime or Cefixime 10 days 75 99% 42 
ceftriaxone 1-6 days 
Children, Cefuroxirne 2-3 days Cefuroxinie axetil 5-8 days 84 98% 52 
acute respiratory tract 
Adults, pneumonia Ofloxacin 6 days Ofloxacin 7 days 103 92% 53 
Children, pneumonia Ceftriaxone 2 days Cefetamet 5 days 108 100% 54 
Ceftriaxone I day Cefetamet 6 days 59 96% 54 
+ 3 days Clarithromycin 7-1 1 days 59 100% 29 
Fleroxacin 4 days 18 61% 25 
complicated urinary tract (or 11 days) (16) 69% 25 
Adults, Fleroxacin 3 days Fleroxacin 4-1 1 days 32 81% 55 
1 Adults, pneumonia Ceftriaxone erythromycin 
Adults, Fleroxacin 3 days 
complicated urinary tract 
“Percentage of patients cured or improved. 
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&om empirical to laboratory-based therapy. They 
suggested that switch to oral therapy only be instituted 
during phase three, but such a policy now seems 
unnecessarily cautious, and many clinicians would be 
happy to switch during phase two. 
In most stules reported so far, intravenous therapy 
has been continued for a mean of at least 2 days, and 
this seems a reasonable target at which to aim. Ramirez 
and Ahkee [29] list the day on which each of 59 patients 
suffering from community-acquired pneumonia was 
switched to oral therapy (clarithromycin) following 
initial intravenous treatment with ceftriaxone plus 
erythromycin. The mean. time to switch was 3.03 days, 
7% being switched on day 1, 27% on day 2, 41% on 
day 3, 14% on day 4, and 12% on day 5. In a similar 
study, Ramirez [30] reported a mean time to switch of 
2.9 days, but there was a time difference between 
switch from intravenous ceftizoxime (median 2 days, 
range 1 to 5) and from intravenous ceftriaxone (median 
4 days, range 1 to 5). 
ENSURING SWITCH IS APPLIED 
The practical difficulties of carrying out clinical trials 
pale into insignificance when compared with the task 
of changing the prescribing habits of an entire hospital 
following a decision to implement a policy of switch. 
While there are some reports of the procedures by 
which this has been done, as customs and practices 
differ widely between various countries and even 
between institutions - for instance, in the relative 
standing of infectious disease physicians, medical 
microbiologists, pharmacists and clinical pharmaco- 
logists, and in the hierarchy of committees deciding 
upon antibiotic policies - it is not necessarily helpful to 
review in detail ways in which individual hospitals have 
come to such decisions. Indeed, there are not enough 
accounts in literature that is generally accessible and in 
sufficient detail to be able to pick more than a few 
salient points [10,21,31-351. 
The original initiative for change may come from 
departments of pharmacy, clinical pharmacology or 
medical microbiology. In many establishments an 
antibiotic advisory sub-committee reports to a phar- 
macy and therapeutics committee, whose recommen- 
dations have to be endorsed by a medical advisory 
board. Once a decision has been made to follow the 
path of switch, guidelines will be produced, imple- 
mented and audited by a multidisciplinary team, 
consisting of an infectious dsease physician, a medical 
microbiologist and a clinical pharmacist. Educational 
programs for physicians, especially those responsible for 
the day-to-day management of patients, are important 
[36]. If an ‘opt out’ approach is taken, all suitable 
patients are automatically switched from a parenteial to 
another appropriate route once criteria are met, unless 
the physician in charge specifically countermands such 
an order [35,37]. In the ‘opt in’ situation, eligible 
patients are identified and a recommendation made for 
each one that switch occur at a suitable time [32,33,38]. 
This recommendation can be reinforced by ‘flagging’ 
notes or attaching labels to charts. An example of the 
latter is given by Woo [38]. Fluorescent stickers have 
been suggested, as they readily catch the eye 133,391, 
but too much reliance should not be placed on these, 
as other stickers may be used to indicate, for example, 
allergies, carriage of methicillin-resistant Staphylococcus 
aureus or diabetic status, and confusion may arise. Precise 
procedures will obviously vary from location to location, 
depending upon circumstances and personalities. 
It is essential to have regular audit procedures to 
make sure that the desired policies are being carried 
out. In three US hospitals where a policy of switch had 
recently been accepted, in more than 80% of suitable 
cases this procedure did actually take place [21,31,32], 
which is clearly a very satisfactory outcome. Rimmer 
[37] noted that compliance with the policy varied 
between specialties, geriatricians being more amenable 
than surgeons. 
ACHIEVEMENT OF COST SAVING BY SWITCH 
As stated above, estimating costs of treatment is a 
difficult and at times controversial exercise. Com- 
parisons certainly cannot properly be made between 
institutions, or from country to country. Cost savings 
will cross interdepartmental boundaries, and may thus 
be very difficult to determine accurately. There does 
seem to be general agreement in the literature that 
switch is cost-effective. For example, Quintiliani et al. 
[21] reported that employing a full-time infectious 
disease physician and a pharmacist for the sole purpose 
of reviewing the notes of patients receiving antibiotic 
treatment with a view to ‘streamlining’ therapy saved 
money far in excess of the extra salary costs involved. 
It  is interesting and perhaps significant that the 
most confident and detailed estimates of cost-saving 
come from the North American continent, where cost 
consciousness seems to have been at a higher level for 
a longer time than elsewhere. Perhaps this is due to the 
fact that more expensive antibiotics are used in the USA 
than in other parts of the world [40]. 
Several calculations have been made of costs saved 
by switch: on a ‘per patient’ basis, estimated savings (in 
US$) vary widely - $1624 for a neutropenic patient 
[41], $1393 [42], $937 [3], $253 [433, $113 [32], and 
$196 and $562 for acquisition costs only [31, 441. O n  
an institutional basis, Rimmer [34] reported a decrease 
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of 6% in spending on cephalosporins, while C o d y  and 
Shafran [45] and Jewesson [33] put figures of $450,000 
and $21,000 on annual savings. Gaunt [46] points out 
that the greatest savings occur when switch takes place 
within 48 h of the initiation of intravenous therapy, and 
it ceases to be cost-effective after 5 days. 
There are further, unquantifiable savings arising 
from successful switch therapy. For example, curtailing 
use of the intravenous route will reduce the number of 
catheter-associated infections, estimated at 1 per 200 
days, each costing $3700 [3]. Patients out of hospital 
also cannot fall prey to other types of nosocomial 
infections, the antibiotics they are taking at home do 
not add to the selection pressure within the hospital, 
and there are advantageous psychological effects, 
especially for children [47]. 
The success of oral therapy may persuade clinicians 
that intravenous therapy may not be required as often 
as at  present perceived [5]. O n  the other hand, another 
possibility is that the shortened course of intravenous 
therapy may prove by itself to be adequate treatment for 
many types of infection, so that the oral arm of switch 
is no longer necessary. This has proved the case for 3- 
day courses of intravenous ciprofloxacin, where up to 
50% of patients did not require any further treatment 
~481. 
CONCLUSIONS 
Substantial savings can be made if switch therapy is 
used, both in acquisition costs - which are easy to see 
- and in hidden costs. Some persuasion may be 
necessary to convince budget holders of the latter truth. 
In order to achieve this, the attention of clinicians 
should be drawn to the possibility of the automatic 
switch option. This task logically ultimately devolves to 
the pharmacists who are responsible for dispensing. 
Precisely how it is done must depend upon local 
circumstances. 
Two or three days is probably long enough for the 
initial intravenous phase of antibiotic treatment. 
From the published data, it appears that an appro- 
priate patient group to target at first comprises those 
with lower respiratory tract infections. Properly organ- 
ized clinical trials are essential to increase confidence in 
what is still a new concept. 
The choice of switch agent is still at present rather 
restricted. There is most experience with cefixime and 
ciprofloxacin, and less with cefuroxime axetil and co- 
amoxiclav. 
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